(OPK) Opko Health - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 959m USD | Total Return: -1.5% in 12m

Diagnostic Tests, Hormones, Vaccines, Therapeutic Antibodies
Total Rating 18
Safety 24
Buy Signal -0.53
Diagnostics & Research
Industry Rotation: +1.9
Market Cap: 959M
Avg Turnover: 2.47M
Risk 3d forecast
Volatility45.1%
VaR 5th Pctl7.15%
VaR vs Median-3.68%
Reward TTM
Sharpe Ratio0.13
Rel. Str. IBD30.2
Rel. Str. Peer Group23.8
Character TTM
Beta0.825
Beta Downside1.011
Hurst Exponent0.414
Drawdowns 3y
Max DD60.12%
CAGR/Max DD-0.04
CAGR/Mean DD-0.07
EPS (Earnings per Share) EPS (Earnings per Share) of OPK over the last years for every Quarter: "2021-03": 0.05, "2021-06": -0.03, "2021-09": 0.04, "2021-12": -0.11, "2022-03": -0.08, "2022-06": -0.14, "2022-09": -0.11, "2022-12": -0.11, "2023-03": -0.02, "2023-06": -0.03, "2023-09": -0.11, "2023-12": -0.09, "2024-03": -0.12, "2024-06": -0.01, "2024-09": 0.03, "2024-12": 0.01, "2025-03": -0.09, "2025-06": -0.08, "2025-09": 0.03, "2025-12": -0.0358, "2026-03": -0.07,
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of OPK over the last years for every Quarter: 2021-03: 545.165, 2021-06: 442.408, 2021-09: 385.813, 2021-12: 401.331, 2022-03: 329.219, 2022-06: 309.893, 2022-09: 179.744, 2022-12: 185.34, 2023-03: 237.577, 2023-06: 265.418, 2023-09: 178.595, 2023-12: 181.9, 2024-03: 173.686, 2024-06: 182.186, 2024-09: 173.632, 2024-12: 183.638, 2025-03: 149.952, 2025-06: 156.807, 2025-09: 151.669, 2025-12: 148.45, 2026-03: 124.196,
Rev. CAGR: -13.95%
Rev. Trend: -97.9%
Last SUE: -0.45
Qual. Beats: 0

Warnings

Interest Coverage Ratio -2.0 is critical

Altman Z'' -7.24 < 1.0 - financial distress zone

Extended 1w

Tailwinds

No distinct edge detected

Description: OPK Opko Health

OPKO Health Inc. (NASDAQ: OPK) is a diversified healthcare organization operating across two primary business segments: Pharmaceuticals and Diagnostics. The company maintains a global presence with operations in North America, Europe, and the Middle East, focusing on the development of multi-specific antibodies, vaccines, and hormonal treatments.

The Pharmaceutical segment manages a pipeline of oncology therapeutics and metabolic products, including Rayaldee and the pediatric growth hormone NGENLA. In the biotechnology sector, companies often utilize multi-specific antibodies to target multiple disease pathways simultaneously, potentially increasing efficacy over traditional monoclonal treatments.

The Diagnostics segment operates under the BioReference brand, providing comprehensive laboratory services ranging from routine molecular diagnostics to specialized genetic testing. This dual-segment model allows the company to balance the high-risk, high-reward nature of drug development with the steady cash flow typically generated by clinical laboratory services.

Investors can further evaluate the underlying fundamentals of this business model at ValueRay.

Headlines to Watch Out For
  • NGENLA royalty revenue growth from Pfizer partnership drives pharmaceutical segment margins
  • BioReference laboratory volume stability impacts core diagnostics revenue and cash flow
  • Rayaldee market penetration in chronic kidney disease patients influences top-line growth
  • Clinical trial progression for tetra-specific antibody oncology pipeline dictates long-term valuation
  • Debt reduction efforts and asset monetization strategies affect overall balance sheet health
Piotroski VR-10 (Strict) 1.5
Net Income: -212.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.09 > 0.02 and ΔFCF/TA 0.31 > 1.0
NWC/Revenue: 66.59% < 20% (prev 64.08%; Δ 2.52% < -1%)
CFO/TA -0.09 > 3% & CFO -163.3m > Net Income -212.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.61 > 1.5 & < 3
Outstanding Shares: last quarter (758.9m) vs 12m ago 13.00% < -2%
Gross Margin: 22.73% > 18% (prev 0.29%; Δ 2.24k% > 0.5%)
Asset Turnover: 29.16% > 50% (prev 32.39%; Δ -3.23% > 0%)
Interest Coverage Ratio: -1.95 > 6 (EBITDA TTM -112.5m / Interest Expense TTM 103.9m)
Altman Z'' -7.24
A: 0.21 (Total Current Assets 535.4m - Total Current Liabilities 148.4m) / Total Assets 1.86b
B: -1.26 (Retained Earnings -2.35b / Total Assets 1.86b)
C: -0.10 (EBIT TTM -202.8m / Avg Total Assets 1.99b)
D: -3.63 (Book Value of Equity -2.37b / Total Liabilities 652.2m)
Altman-Z'' = -7.24 = D
Beneish M -2.88
DSRI: 0.99 (Receivables 107.6m/128.7m, Revenue 581.1m/689.4m)
GMI: 1.27 (GM 22.73% / 28.89%)
AQI: 1.08 (AQ_t 0.65 / AQ_t-1 0.60)
SGI: 0.84 (Revenue 581.1m / 689.4m)
TATA: -0.03 (NI -212.9m - CFO -163.3m) / TA 1.86b)
Beneish M = -2.88 (Cap -4..+1) = A
What is the price of OPK shares?

As of May 27, 2026, the stock is trading at USD 1.29 with a total of 2,466,941 shares traded.
Over the past week, the price has changed by +14.16%, over one month by +7.50%, over three months by +7.50% and over the past year by -1.53%.

Is OPK a buy, sell or hold?

Opko Health has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy OPK.

  • StrongBuy: 2
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the OPK price?
Analysts Target Price 3.8 191.5%
Opko Health (OPK) - Fundamental Data Overview as of 27 May 2026
Market Cap USD = 959.0m (959.0m USD * 1.0 USD.USD)
P/E Forward = 53.7634
P/S = 1.6502
P/B = 0.7992
P/EG = 93.6471
Revenue TTM = 581.1m USD
EBIT TTM = -202.8m USD
EBITDA TTM = -112.5m USD
Long Term Debt = 336.0m USD (from longTermDebt, last quarter)
Short Term Debt = 22.3m USD (from shortTermDebt, last quarter)
Debt = 448.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.3m
Net Debt = 106.3m USD (calculated: Debt 448.2m - CCE 341.9m)
Enterprise Value = 1.07b USD (959.0m + Debt 448.2m - CCE 341.9m)
Interest Coverage Ratio = -1.95 (Ebit TTM -202.8m / Interest Expense TTM 103.9m)
EV/FCF = -6.11x (Enterprise Value 1.07b / FCF TTM -174.2m)
FCF Yield = -16.35% (FCF TTM -174.2m / Enterprise Value 1.07b)
FCF Margin = -29.98% (FCF TTM -174.2m / Revenue TTM 581.1m)
Net Margin = -36.64% (Net Income TTM -212.9m / Revenue TTM 581.1m)
Gross Margin = 22.73% ((Revenue TTM 581.1m - Cost of Revenue TTM 449.0m) / Revenue TTM)
Gross Margin QoQ = 21.57% (prev 30.29%)
Tobins Q-Ratio = 0.57 (Enterprise Value 1.07b / Total Assets 1.86b)
Interest Expense / Debt = 23.19% (Interest Expense 103.9m / Debt 448.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -160.2m (EBIT -202.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.61 (Total Current Assets 535.4m / Total Current Liabilities 148.4m)
Debt / Equity = 0.37 (Debt 448.2m / totalStockholderEquity, last quarter 1.20b)
 Debt / EBITDA = -0.94 (negative EBITDA) (Net Debt 106.3m / EBITDA -112.5m)
 Debt / FCF = -0.61 (negative FCF - burning cash) (Net Debt 106.3m / FCF TTM -174.2m)
 Total Stockholder Equity = 1.27b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.69% (Net Income -212.9m / Total Assets 1.86b)
RoE = -5.89% (Net Income TTM -212.9m / Total Stockholder Equity 3.61b)
RoCE = -5.13% (EBIT -202.8m / Capital Employed (Equity 3.61b + L.T.Debt 336.0m))
 RoIC = -9.42% (negative operating profit) (NOPAT -160.2m / Invested Capital 1.70b)
 WACC = 11.89% (E(959.0m)/V(1.41b) * Re(8.88%) + D(448.2m)/V(1.41b) * Rd(23.19%) * (1-Tc(0.21)))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 6.67 | Cagr: 0.43%
 [DCF] Fair Price = unknown (Cash Flow -174.2m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -97.89 | Revenue CAGR: -13.95% | SUE: -0.45 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=N/A | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=-37.50% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=-0.38 | Chg30d=-11.76% | Revisions=-20% | GrowthEPS=+16.7% | GrowthRev=-11.4%
EPS next Year (2027-12-31): EPS=-0.32 | Chg30d=+3.03% | Revisions=+20% | GrowthEPS=+15.8% | GrowthRev=+5.5%